The first and only anti-VEGF FDA approved for myopic choroidal neovascularization (mCNV) 1

LUCENTIS® (ranibizumab injection) is indicated for the treatment of patients with myopic choroidal neovascularization (mCNV).

Study design 1,9

RADIANCE was a randomized, double-masked, active-controlled study in patients with mCNV comparing 3 treatment groups, with key clinical outcomes at Month 3:

  • Group I (n=105): LUCENTIS 0.5 mg, treatment guided by vision stabilitya
  • Group II (n=116): LUCENTIS 0.5 mg, treatment guided by disease activityb
  • Group III (n=55): active control vPDT (verteporfin photodynamic therapy)
  • Patient age ranged from 18-87 years, with a mean age of 55 years

a The retreatment criteria in Group I were vision stability guided, with the BCVA at the current visit being assessed for changes compared with the two preceding monthly BCVA values.
b The retreatment criteria in Group II were disease activity guided, based on BCVA decrease from the previous visit that was attributable to intra- or sub-retinal fluid or active leakage secondary to mCNV as assessed by OCT and/or FA compared to the previous monthly visit. 

Significant vision improvement over 3 months in patients with mCNV 1,9

The proportion of patients who gained ≥15 letters (ETDRS) by Month 3 was 37.1% and 40.5% for LUCENTIS Groups I and II, respectively, and 14.5% for the vPDT group (P<0.01; 95% CI: Group I [9.5, 35.7], Group II [13.1, 38.9]).

Mean BCVA Change from Baseline to Month 3 Chart (ETDRS Letters x Months)

Dosing frequency in patients with mCNV 1

Mean number of LUCENTIS 0.5 mg injections between baseline and Month 3: 2.5 injections in Group 1 (VA Stabilization) and 1.8 injections in Group 2 (Disease Activity). 41% of patients received 1, 2, or 3 injections between baseline and Month 3 with no injection afterwards.

BCVA, best corrected visual acuity; CI, confidence interval; ETDRS, Early Treatment Diabetic Retinopathy Scale; FA, fluorescein angiography; OCT, optical coherence tomography; VA, visual acuity; VEGF, vascular endothelial growth factor.

Resources for your patients.
LUCENTIS Co-pay Program
Support for your patients with commercial insurance.
LUCENTIS Access Solutions
Genentech Access Solutions is your resource for access and reimbursement support services.